APGE Apogee Therapeutics, Inc.
Price Chart
Executive Summary
Apogee Therapeutics announced positive 16-week induction dose optimization results from Part B of the Phase 2 APEX trial of zumilokibart in moderate-to-severe atopic dermatitis. The mid-dose met all primary and secondary endpoints with high statistical significance (EASI-75 65.9% vs 23.4% placebo, p<0.001), supporting planned Phase 3 initiation in 2H 2026. The company also disclosed a strategic financing collaboration with Blackstone Life Sciences expected to provide funding through commercialization without need for future equity financing.
Actionable Insight
This is a major derisking catalyst for APGE. The Phase 2 Part B data confirms zumilokibart's best-in-class potential with robust efficacy and transformative dosing (2-4 dosing days/year vs 26 for DUPIXENT). The Blackstone financing removes equity dilution overhang. Key catalysts ahead: Phase 3 initiation 2H 2026, 52-week Part B data 1H 2027, Phase 3 readouts 2028. Monitor for regulatory feedback on Phase 3 dose and any competitive updates from Sanofi's amlitelimab.
Key Facts
- APEX Part B met primary endpoint: mid-dose EASI-75 65.9% vs placebo 23.4% (p<0.001)
- Mid-dose secondary endpoints all met: IGA 0/1 46.0% (p<0.001), EASI-90 47.4% (p<0.001), I-NRS4 50.5% (p<0.001), EASI-100 16.5% (p<0.01), vLDA 20.6% (p<0.01)
- Mid-dose selected as planned Phase 3 dose; Phase 3 ADventure program (3 trials) expected to initiate 2H 2026
- Blackstone collaboration provides up to $1.3B in funding including $400M pre-approval and up to $400M approval tranche; max royalty rate 6.25% on up to $5B of WW annual sales
- Zumilokibart well-tolerated; pooled conjunctivitis rate 10.6% for mid-dose
- Phase 2b ASPIRE asthma trial expected 1H 2027; Phase 2a ELEVATE EoE trial expected 2H 2026
- Launch anticipated in 2029
Financial Impact
Blackstone financing provides up to $1.3B; Apogee had $1.3B cash as of March 31, 2026; total capital expected to fund through commercialization without equity financing
Risk Factors
- Phase 3 trials may fail to replicate Phase 2 results
- Competitive landscape evolving (amlitelimab, other IL-13/IL-4 agents)
- Conjunctivitis rate (10.6%) may be scrutinized by regulators
- Blackstone royalty obligation (up to 6.25% on first $5B sales) reduces peak margin
- Regulatory interactions could delay Phase 3 initiation timeline
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-066572 |
| Document: tm2615568d1_8k.htm | 0001104659-26-066572 |
| Document: tm2615568d1_ex99-1.htm | 0001104659-26-066572 |
| Document: 0001104659-26-066572-index-headers.html | 0001104659-26-066572 |
| Document: 0001104659-26-066572-index.html | 0001104659-26-066572 |
| Document: 0001104659-26-066572.txt | 0001104659-26-066572 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 27, 2026
13d ago
|
8-K
| $77.75 $78.71 | ▲ +1.23% | ▲ +0.03% | $83.01 (+6.77%) |
|
May 27, 2026
13d ago
|
8-K
| $77.75 $78.71 | ▲ +1.23% | ▲ +0.03% | $83.01 (+6.77%) |
|
May 27, 2026
13d ago
|
Press Release
| $77.75 $78.71 | ▲ +1.23% | ▲ +0.03% | $83.01 (+6.77%) |
|
May 27, 2026
13d ago
|
Press Release
| $77.75 $78.71 | ▲ +1.23% | ▲ +0.03% | $83.01 (+6.77%) |
|
May 26, 2026
14d ago
|
Press Release
| $77.75 $78.71 | ▲ +1.23% | ▲ +0.03% | $83.01 (+6.77%) |
|
May 16, 2026
25d ago
|
Insider Cluster
| $78.75 $82.81 | ▲ +5.16% | ▲ +3.54% | $83.01 (+5.41%) |
|
May 13, 2026
27d ago
|
144
| $83.94 $81.39 | ▼ −3.04% | ▼ −2.90% | $83.01 (−1.11%) |
|
May 11, 2026
29d ago
|
8-K
| $84.60 $78.75 | ▼ −6.91% | ▼ −6.83% | $83.01 (−1.88%) |
|
May 11, 2026
29d ago
|
Press Release
| $84.60 $78.75 | ▼ −6.91% | ▼ −6.83% | $83.01 (−1.88%) |
|
May 1, 2026
5w ago
|
Insider Cluster
| $80.75 $83.03 | ▲ +2.82% | ▲ +0.48% | $83.01 (+2.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access